San Diego's Astute Medical Inc. announced a strategic collaboration with Ortho-Clinical Diagnostics Inc. (OCD) that will expand access to a new test that assesses critically ill patients for risk of acute kidney injury (AKI), a prevalent and deadly condition.
Under the terms of the multi-year agreement, Astute Medical has designated OCD as the exclusive sales agent for Astute's NephroCheck Test and Astute140 Meter in certain countries of the European Union and, if approved, in the United States. The NephroCheck Test and the Astute140 Meter are currently not available for sale in the United States. Astute Medical is pursuing regulatory clearance to market the NephroCheck Test and the Astute140 Meter in the United States.
Astute has also granted OCD a semi-exclusive worldwide license to develop and commercialize a version of the NephroCheck Test for use on its VITROS line of automated, high-volume testing platforms. The test developed for the OCD platform will require separate regulatory clearances before it can be sold.
As a part of the strategic collaboration, OCD has made a $15 million equity investment in Astute Medical. The companies did not disclose further financial details of the agreement.